US Stock MarketDetailed Quotes

Contineum Therapeutics (CTNM)

Watchlist
  • 13.530
  • +0.230+1.73%
Close Apr 17 16:00 ET
  • 13.530
  • 0.0000.00%
Post 16:10 ET
505.16MMarket Cap-6.24P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Contineum Therapeutics (CTNM) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
33.73%68.06M
0.40%17.12M
15.09%14.93M
63.58%17.9M
82.38%18.11M
50.03%50.89M
76.18%17.05M
60.79%12.97M
-1.08%10.94M
94.13%9.93M
Selling and administrative expenses
32.59%16.54M
8.13%4.36M
21.38%3.94M
26.16%3.84M
104.37%4.4M
97.34%12.47M
142.31%4.03M
106.75%3.25M
89.83%3.04M
45.11%2.15M
-General and administrative expense
32.59%16.54M
8.13%4.36M
21.38%3.94M
26.16%3.84M
104.37%4.4M
97.34%12.47M
142.31%4.03M
106.75%3.25M
89.83%3.04M
45.11%2.15M
Research and development costs
34.10%51.52M
-2.00%12.76M
12.99%10.99M
77.99%14.06M
76.29%13.71M
39.20%38.42M
62.44%13.02M
49.68%9.73M
-16.48%7.9M
114.15%7.78M
Operating profit
-33.73%-68.06M
-0.40%-17.12M
-15.09%-14.93M
-63.58%-17.9M
-82.38%-18.11M
-416.56%-50.89M
-76.18%-17.05M
-60.79%-12.97M
-128.11%-10.94M
-94.13%-9.93M
Net non-operating interest income expense
-7.40%8.25M
-20.49%2.01M
-28.60%1.96M
1.40%2.03M
37.53%2.25M
102.48%8.91M
41.23%2.53M
57.89%2.74M
255.42%2M
429.45%1.64M
Non-operating interest income
-7.40%8.25M
-20.49%2.01M
-28.60%1.96M
1.40%2.03M
37.53%2.25M
93.33%8.91M
41.23%2.53M
57.89%2.74M
194.70%2M
307.98%1.64M
Non-operating interest expense
----
----
----
----
----
--0
--0
--0
--0
--0
Other net income (expense)
38.66%-165K
-10.87%-51K
638.24%183K
-153.03%-167K
-5.69%-130K
-109.98%-269K
-4.55%-46K
5.56%-34K
-102.36%-66K
-583.33%-123K
Gain on sale of security
----
----
----
----
----
-2,220.00%-106K
-66.67%1K
----
450.00%11K
---117K
Special income (charges)
----
----
----
----
----
--0
--0
--0
--0
----
Other non- operating income (expenses)
-1.23%-165K
-8.51%-51K
638.24%183K
-116.88%-167K
-2,066.67%-130K
7.91%-163K
0.00%-47K
5.56%-34K
-1.32%-77K
66.67%-6K
Income before tax
-41.93%-59.98M
-4.06%-15.16M
-24.59%-12.79M
-78.04%-16.04M
-89.97%-15.99M
-282.38%-42.26M
-83.67%-14.57M
-61.20%-10.27M
-121.30%-9.01M
-74.48%-8.42M
Income tax
0
0
0
0
0
Net income
-41.93%-59.98M
-4.06%-15.16M
-24.59%-12.79M
-78.04%-16.04M
-89.97%-15.99M
-285.99%-42.26M
-87.48%-14.57M
-64.25%-10.27M
-121.68%-9.01M
-74.48%-8.42M
Net income continuous Operations
-41.93%-59.98M
-4.06%-15.16M
-24.59%-12.79M
-78.04%-16.04M
-89.97%-15.99M
-285.99%-42.26M
-87.48%-14.57M
-64.25%-10.27M
-121.68%-9.01M
-74.48%-8.42M
Minority interest income
Net income attributable to the parent company
-41.93%-59.98M
-4.06%-15.16M
-24.59%-12.79M
-78.04%-16.04M
-89.97%-15.99M
-285.99%-42.26M
-87.48%-14.57M
-64.25%-10.27M
-121.68%-9.01M
-74.48%-8.42M
Preferred stock dividends
Other preferred stock dividends
0
0
Net income attributable to common stockholders
-41.93%-59.98M
-4.06%-15.16M
-24.59%-12.79M
-78.04%-16.04M
-89.97%-15.99M
-285.99%-42.26M
-179.24%-14.57M
-64.25%-10.27M
-253.50%-9.01M
-74.48%-8.42M
Basic earnings per share
0.46%-2.17
12.50%-0.49
-12.50%-0.45
-58.97%-0.62
-99.29%-0.62
-359.60%-2.18
-182.43%-0.56
-73.13%-0.4
-210.80%-0.39
-7.53%-0.3111
Diluted earnings per share
0.46%-2.17
12.50%-0.49
-12.50%-0.45
-58.97%-0.62
-99.29%-0.62
-359.60%-2.18
-182.43%-0.56
-73.13%-0.4
-334.88%-0.39
-7.53%-0.3111
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense 33.73%68.06M0.40%17.12M15.09%14.93M63.58%17.9M82.38%18.11M50.03%50.89M76.18%17.05M60.79%12.97M-1.08%10.94M94.13%9.93M
Selling and administrative expenses 32.59%16.54M8.13%4.36M21.38%3.94M26.16%3.84M104.37%4.4M97.34%12.47M142.31%4.03M106.75%3.25M89.83%3.04M45.11%2.15M
-General and administrative expense 32.59%16.54M8.13%4.36M21.38%3.94M26.16%3.84M104.37%4.4M97.34%12.47M142.31%4.03M106.75%3.25M89.83%3.04M45.11%2.15M
Research and development costs 34.10%51.52M-2.00%12.76M12.99%10.99M77.99%14.06M76.29%13.71M39.20%38.42M62.44%13.02M49.68%9.73M-16.48%7.9M114.15%7.78M
Operating profit -33.73%-68.06M-0.40%-17.12M-15.09%-14.93M-63.58%-17.9M-82.38%-18.11M-416.56%-50.89M-76.18%-17.05M-60.79%-12.97M-128.11%-10.94M-94.13%-9.93M
Net non-operating interest income expense -7.40%8.25M-20.49%2.01M-28.60%1.96M1.40%2.03M37.53%2.25M102.48%8.91M41.23%2.53M57.89%2.74M255.42%2M429.45%1.64M
Non-operating interest income -7.40%8.25M-20.49%2.01M-28.60%1.96M1.40%2.03M37.53%2.25M93.33%8.91M41.23%2.53M57.89%2.74M194.70%2M307.98%1.64M
Non-operating interest expense ----------------------0--0--0--0--0
Other net income (expense) 38.66%-165K-10.87%-51K638.24%183K-153.03%-167K-5.69%-130K-109.98%-269K-4.55%-46K5.56%-34K-102.36%-66K-583.33%-123K
Gain on sale of security ---------------------2,220.00%-106K-66.67%1K----450.00%11K---117K
Special income (charges) ----------------------0--0--0--0----
Other non- operating income (expenses) -1.23%-165K-8.51%-51K638.24%183K-116.88%-167K-2,066.67%-130K7.91%-163K0.00%-47K5.56%-34K-1.32%-77K66.67%-6K
Income before tax -41.93%-59.98M-4.06%-15.16M-24.59%-12.79M-78.04%-16.04M-89.97%-15.99M-282.38%-42.26M-83.67%-14.57M-61.20%-10.27M-121.30%-9.01M-74.48%-8.42M
Income tax 00000
Net income -41.93%-59.98M-4.06%-15.16M-24.59%-12.79M-78.04%-16.04M-89.97%-15.99M-285.99%-42.26M-87.48%-14.57M-64.25%-10.27M-121.68%-9.01M-74.48%-8.42M
Net income continuous Operations -41.93%-59.98M-4.06%-15.16M-24.59%-12.79M-78.04%-16.04M-89.97%-15.99M-285.99%-42.26M-87.48%-14.57M-64.25%-10.27M-121.68%-9.01M-74.48%-8.42M
Minority interest income
Net income attributable to the parent company -41.93%-59.98M-4.06%-15.16M-24.59%-12.79M-78.04%-16.04M-89.97%-15.99M-285.99%-42.26M-87.48%-14.57M-64.25%-10.27M-121.68%-9.01M-74.48%-8.42M
Preferred stock dividends
Other preferred stock dividends 00
Net income attributable to common stockholders -41.93%-59.98M-4.06%-15.16M-24.59%-12.79M-78.04%-16.04M-89.97%-15.99M-285.99%-42.26M-179.24%-14.57M-64.25%-10.27M-253.50%-9.01M-74.48%-8.42M
Basic earnings per share 0.46%-2.1712.50%-0.49-12.50%-0.45-58.97%-0.62-99.29%-0.62-359.60%-2.18-182.43%-0.56-73.13%-0.4-210.80%-0.39-7.53%-0.3111
Diluted earnings per share 0.46%-2.1712.50%-0.49-12.50%-0.45-58.97%-0.62-99.29%-0.62-359.60%-2.18-182.43%-0.56-73.13%-0.4-334.88%-0.39-7.53%-0.3111
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +14.09%
Sample Name
Sample Code
 +3.93%
Sample Name
Sample Code
 +2.06%
4
United States Oil Fund LP
USO
-1.12%
5
United States Gasoline Fund Lp
UGA
-2.10%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +22.28%
Sample Name
Sample Code
 +20.52%
Sample Name
Sample Code
 +19.71%
4
Zai Lab
ZLAB
+16.97%
5
Legend Biotech
LEGN
+16.57%
View More
Middle East conflict spreads to the stock market! How should investors respond?
Lebanon and Israel will implement a 10-day ceasefire! Iran's foreign minister, based on the Lebanon ceasefire agreement, announced the compl Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -